国泰海通证券股份有限公司 关于 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金 之 独立财务顾问报告 （修订稿） 独立财务顾问 签署日期：二〇二五年九月 声明与承诺 本部分所使用的简称与本报告"释义"中所定义的简称具有相同含义。 国泰海通证券股份有限公司接受上海奥浦迈生物科技股份有限公司的委托， 担任上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配 套资金的独立财务顾问，就该事项向上海奥浦迈生物科技股份有限公司全体股东 提供独立意见，并制作本独立财务顾问报告。 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管 理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》 《上海证券交易所上市公司自律监管指引第 6 号—重大资产重组》 等法律、法规的有关规定，按照证券行业公认的业务标准、道德规范和诚实信用、 勤勉尽责精神，遵循客观、公正的原则，在认真审阅相关资料和充分了解本次交 易行为的基础上，发表独立财务顾问意见，旨在就本次交易做出独立、客观和公 ...

Core Viewpoint - Shanghai Aopumai Biotechnology Co., Ltd. plans to acquire 100% equity of Pengli Biotechnology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, involving multiple investment partners [1][3]. Group 1: Acquisition Details - The acquisition involves multiple investment entities, including PharmaLegacy Hong Kong Limited and several limited partnerships, indicating a broad consortium of investors [1]. - The company intends to raise supporting funds by issuing shares to no more than 35 specific investors as part of this transaction [3]. Group 2: Regulatory Compliance - The transaction is in accordance with the "Major Asset Restructuring Management Measures" which stipulates that continuous purchases or sales of the same or related assets within twelve months must be cumulatively calculated [3][4]. - The assets involved in the transaction are recognized as belonging to the same or similar business scope, thus requiring inclusion in the cumulative calculation for this transaction [5]. Group 3: Financial Adjustments - The company has adjusted its capital increase plan for its subsidiary, increasing the planned investment from 20 million RMB to 5 million RMB, reflecting a strategic shift in resource allocation [4]. - The company has also made additional investments in other subsidiaries, such as a 42 million RMB increase in Suzhou Haixing Biotechnology Co., Ltd., acquiring a 30.0014% stake [4][5].